oral, selective PKC_ kinase inhibitor
Ph. I candidate for Psoriasis
from screen of internal library and SBDD
Journal of Medicinal Chemistry
Celgene/BMS, San Diego, CA, USA
CC-90005
The Celgene/BMS PKCθ kinase inhibitor, CC-90005, highlighted by Julien Lefranc, is a clinical candidate in Ph. I for psoriasis, with some dosing being conducted in healthy volunteers. The safety profile is…